Thus, Survivin compartmentalization appears to be an important predictive biomarker for alkylation drug-based glioblastoma therapy and manipulating Survivin subcellular localization towards permanent trapping in the nucleus would facilitate TMZ response of malignant gliomas. The gene discussed is BIRC5; the disease is malignant glioma.